Q
QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,607 signal articles · 111 in last 24h · 155,469 total before filter · latest 1h ago
111last 24h
852last 7d
144● bullish (7d)
90● bearish (7d)
214publishers
AllMacro190Earnings105M&A125Regulatory20Product22Analyst19
✕ clear all filterssentiment: bearishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Investing.com24d agobearish
MongoDB stock tumbles despite earnings beat on profit-taking

Investing.com -- MongoDB (NASDAQ:MDB) reported second quarter fiscal 2027 results that exceeded analyst expectations, with adjusted earnings per share of $1.90 beating the consensus estimate of $1.61, while revenue of $771.8 million surpassed the $735.16 million estimate. Revenue increased 30% YoY, marking the highest growth rate in several years.

Investing.com24d agobearish
BofA cuts PG&E to Neutral as California wildfire reforms fall short

Investing.com -- Bank of America downgraded PG&E Corp. to Neutral from Buy on Tuesday, saying California's latest wildfire legislation failed to provide the durable liability and financing framework needed to support the utility's ambitious investment plans.

MongoDB’s (NASDAQ:MDB) Q2 CY2026: Strong Sales But Stock Drops 13.7%
StockStory24d agobearish
MongoDB’s (NASDAQ:MDB) Q2 CY2026: Strong Sales But Stock Drops 13.7%

Database platform company MongoDB (NASDAQ:MDB) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 30.5% year on year to $771.8 million. Guidance for next quarter’s revenue was better than expected at $758.5 million at the midpoint, 1.8% above analysts’ estimates. Its non-GAAP profit of $1.90 per share was 18.1% above analysts’ consensus estimates.

Hims & Hers falls after FDA crackdown on unapproved weight-loss drugs
Proactive24d agobearish
Hims & Hers falls after FDA crackdown on unapproved weight-loss drugs

Hims & Hers Health (NYSE:HIMS) shares fell 3.2% after the FDA warned telehealth companies and compounding pharmacies over unapproved weight-loss drugs, including versions of semaglutide, tirzepatide and retatrutide. The agency said retatrutide and cagrilintide cannot legally be used in...